These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 28636956)

  • 41. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
    Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers.
    Carnathan DG; Kaushik K; Ellebedy AH; Enemuo CA; Gebru EH; Dhadvai P; Rasheed MAU; Pauthner MG; Ozorowski G; Ahmed R; Burton DR; Ward AB; Silvestri G; Crotty S; Locci M
    Front Immunol; 2020; 11():1213. PubMed ID: 32612608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses.
    Bale S; Goebrecht G; Stano A; Wilson R; Ota T; Tran K; Ingale J; Zwick MB; Wyatt RT
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.
    Patricia D'Souza M; Allen MA; Baumblatt JAG; Boggiano C; Crotty S; Grady C; Havenar-Daughton C; Heit A; Hu DJ; Kunwar N; McElrath MJ;
    Vaccine; 2018 Sep; 36(38):5671-5677. PubMed ID: 30097219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.
    Sliepen K; Han BW; Bontjer I; Mooij P; Garces F; Behrens AJ; Rantalainen K; Kumar S; Sarkar A; Brouwer PJM; Hua Y; Tolazzi M; Schermer E; Torres JL; Ozorowski G; van der Woude P; de la Peña AT; van Breemen MJ; Camacho-Sánchez JM; Burger JA; Medina-Ramírez M; González N; Alcami J; LaBranche C; Scarlatti G; van Gils MJ; Crispin M; Montefiori DC; Ward AB; Koopman G; Moore JP; Shattock RJ; Bogers WM; Wilson IA; Sanders RW
    Nat Commun; 2019 May; 10(1):2355. PubMed ID: 31142746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits.
    Yang YR; McCoy LE; van Gils MJ; Andrabi R; Turner HL; Yuan M; Cottrell CA; Ozorowski G; Voss J; Pauthner M; Polveroni TM; Messmer T; Wilson IA; Sanders RW; Burton DR; Ward AB
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization.
    Bianchi M; Turner HL; Nogal B; Cottrell CA; Oyen D; Pauthner M; Bastidas R; Nedellec R; McCoy LE; Wilson IA; Burton DR; Ward AB; Hangartner L
    Immunity; 2018 Aug; 49(2):288-300.e8. PubMed ID: 30097292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle.
    Brouwer PJM; Antanasijevic A; Berndsen Z; Yasmeen A; Fiala B; Bijl TPL; Bontjer I; Bale JB; Sheffler W; Allen JD; Schorcht A; Burger JA; Camacho M; Ellis D; Cottrell CA; Behrens AJ; Catalano M; Del Moral-Sánchez I; Ketas TJ; LaBranche C; van Gils MJ; Sliepen K; Stewart LJ; Crispin M; Montefiori DC; Baker D; Moore JP; Klasse PJ; Ward AB; King NP; Sanders RW
    Nat Commun; 2019 Sep; 10(1):4272. PubMed ID: 31537780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.
    Wang S; Matassoli F; Zhang B; Liu T; Shen CH; Bylund T; Johnston T; Henry AR; Teng IT; Tripathi P; Becker JE; Changela A; Chaudhary R; Cheng C; Gaudinski M; Gorman J; Harris DR; Lee M; Morano NC; Novik L; O'Dell S; Olia AS; Parchment DK; Rawi R; Roberts-Torres J; Stephens T; Tsybovsky Y; Wang D; Van Wazer DJ; Zhou T; Doria-Rose NA; Koup RA; Shapiro L; Douek DC; McDermott AB; Kwong PD
    Cell Rep; 2023 Jul; 42(7):112755. PubMed ID: 37436899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.
    Francica JR; Laga R; Lynn GM; Mužíková G; Androvič L; Aussedat B; Walkowicz WE; Padhan K; Ramirez-Valdez RA; Parks R; Schmidt SD; Flynn BJ; Tsybovsky Y; Stewart-Jones GBE; Saunders KO; Baharom F; Petrovas C; Haynes BF; Seder RA
    PLoS Biol; 2019 Jun; 17(6):e3000328. PubMed ID: 31206510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates.
    Steichen JM; Phung I; Salcedo E; Ozorowski G; Willis JR; Baboo S; Liguori A; Cottrell CA; Torres JL; Madden PJ; Ma KM; Sutton HJ; Lee JH; Kalyuzhniy O; Allen JD; Rodriguez OL; Adachi Y; Mullen TM; Georgeson E; Kubitz M; Burns A; Barman S; Mopuri R; Metz A; Altheide TK; Diedrich JK; Saha S; Shields K; Schultze SE; Smith ML; Schiffner T; Burton DR; Watson CT; Bosinger SE; Crispin M; Yates JR; Paulson JC; Ward AB; Sok D; Crotty S; Schief WR
    Science; 2024 May; 384(6697):eadj8321. PubMed ID: 38753769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
    Antanasijevic A; Ueda G; Brouwer PJM; Copps J; Huang D; Allen JD; Cottrell CA; Yasmeen A; Sewall LM; Bontjer I; Ketas TJ; Turner HL; Berndsen ZT; Montefiori DC; Klasse PJ; Crispin M; Nemazee D; Moore JP; Sanders RW; King NP; Baker D; Ward AB
    PLoS Pathog; 2020 Aug; 16(8):e1008665. PubMed ID: 32780770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Native-like Env trimers as a platform for HIV-1 vaccine design.
    Sanders RW; Moore JP
    Immunol Rev; 2017 Jan; 275(1):161-182. PubMed ID: 28133806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.